FGFR2 and gastric cancer: Bemarituzumab, a first-in-class humanized IgG2 monoclonal antibody plus first-line chemotherapy (oxaliplatin, 5-fluorouracil, leucovorin, and FOLFOX), demonstrated improved overall survival in patients with FGFR2+ GC [44].